Collectionner le produit
Détails du produit
Source
Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (SPD-M128) is a chimeric monoclonal antibody combining the constant domains of the human IgG1 molecule with mouse variable regions. Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
Clone
AM128
Isotype
Human IgG1, Kappa
Reactivity
Virus
Specificity
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
Application
ApplicationRecommended UsageELISA0.2-2 μg/mLPurification
Protein A purified / Protein G purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Bioactivity-ELISA
Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (Cat. No. SPD-M128) with a linear range of 0.05-0.78 ng/mL (QC tested).
Protocol
Serial dilutions of Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (Cat. No. SPD-M128) was detected by SARS-CoV-2 Inhibitor screening Kit with a half maximal inhibitory concentration (IC50) of 1.197 μg/mL (Routinely tested).
Protocol
Serial dilutions of Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody (Cat. No. SPD-M128) was incubated with SARS-CoV-2 pseudotyped virus at 37 °C for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37 °C for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 0.03255 nM using the Reed-Muench method.
Protocol
Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat.No. SPD-M128) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD:ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1 mutant and treated with the antibody at increasing concentration. Percent inhibition is calculated based on the OD value.
Protocol
Bioactivity-BLI
Loaded Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (Cat. No. SPD-M128) on AHC Biosensor, can bind SARS-CoV-2 S1 protein, His Tag with an affinity constant of 4.42 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
Contact Us
Drug Candidate Licensing
